The changing landscape of breast cancer prognostic prediction
We increasingly recognize that multiple factors influence disease outcome in breast cancer. A series of papers in the BJC shed new lights on how the method of diagnosis (screen detected versus self-detected), timing of initiation of therapy, factors that influence treatment compliance, and molecular features of the cancer contribute to treatment outcome. Understanding these variables that influence survival is critical for making optimal treatment recommendations in the clinic and also defines areas for future research.
Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer Open
E A Rakha, D Soria, A R Green, C Lemetre, D G Powe, C C Nolan, J M Garibaldi, G Ball and I O Ellis
British Journal of Cancer 110: 1688-1697; Published online, 11 March 2014; doi:10.1038/bjc.2014.120
Breast cancer survival and prognosis by screening history Open
A J Coldman and N Phillips
British Journal of Cancer 110: 556-559; Published online, 03 December 2013; doi:10.1038/bjc.2013.732
Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study Open
C A Purdie, P Quinlan, L B Jordan, A Ashfield, S Ogston, J A Dewar and A M Thompson
British Journal of Cancer 110: 565-572; Published online, 03 December 2013; doi:10.1038/bjc.2013.756
Predicting response and survival in chemotherapy-treated triple-negative breast cancer Open
A Prat, A Lluch, J Albanell, W T Barry, C Fan, J I Chacón, J S Parker, L Calvo, A Plazaola, A Arcusa, M A Seguí-Palmer, O Burgues, N Ribelles, A Rodriguez-Lescure, A Guerrero, M Ruiz-Borrego, B Munarriz, J A López, B Adamo, M C U Cheang, Y Li, Z Hu, M L Gulley, M J Vidal, B N Pitcher, M C Liu, M L Citron, M J Ellis, E Mardis, T Vickery, C A Hudis, E P Winer, L A Carey, R Caballero, E Carrasco, M Martín, C M Perou and E Alba
British Journal of Cancer 111: 1532-1541; Published online, 07 August 2014; doi:10.1038/bjc.2014.444
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients Open
P Dubsky, J C Brase, R Jakesz, M Rudas, C F Singer, R Greil, O Dietze, I Luisser, E Klug, R Sedivy, M Bachner, D Mayr, M Schmidt, M C Gehrmann, C Petry, K E Weber, K Fisch, R Kronenwett, M Gnant and M Filipits
British Journal of Cancer 109: 2959-2964; Published online, 24 October 2013; doi:10.1038/bjc.2013.671
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial Open
M Gnant, G Pfeiler, H Stöger, B Mlineritsch, F Fitzal, M Balic, W Kwasny, M Seifert, M Stierer, P Dubsky, R Greil, G Steger, H Samonigg, C Fesl and R Jakesz
British Journal of Cancer 109: 589-596; Published online, 18 July 2013; doi:10.1038/bjc.2013.367
Clinical relevance of lymph node ratio in breast cancer patients with one to three positive lymph nodes Open
S I Kim, S-H Cho, J S Lee, H-G Moon, W C Noh, H J Youn, B K Ko and B-W Park
British Journal of Cancer 109: 1165-1171; Published online, 13 August 2013; doi:10.1038/bjc.2013.465
Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts Open
B M Syed, A R Green, E C Paish, D Soria, J Garibaldi, L Morgan, D A L Morgan, I O Ellis and K L Cheung
British Journal of Cancer 108: 1042-1051; Published online, 05 March 2013; doi:10.1038/bjc.2012.601
Is elective nodal irradiation beneficial in patients with pathologically negative lymph nodes after neoadjuvant chemotherapy and breast-conserving surgery for clinical stage II–III breast cancer? A multicentre retrospective study (KROG 12-05) Open
J M Noh, W Park, C-O Suh, K C Keum, Y B Kim, K H Shin, K Kim, E K Chie, S W Ha, S S Kim, S D Ahn, H S Shin, J H Kim, H-S Lee, N K Lee, S J Huh and D H Choi
British Journal of Cancer 110: 1420-1426; Published online, 30 January 2014; doi:10.1038/bjc.2014.26
The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study Open
C McCowan, S Wang, A M Thompson, B Makubate and D J Petrie
British Journal of Cancer 109: 1172-1180; Published online, 15 August 2013; doi:10.1038/bjc.2013.464
Individual risk profiling for breast cancer recurrence: towards tailored follow-up schemes Open
J Kraeima, S Siesling, I M H Vliegen, J M Klaase and M J IJzerman
British Journal of Cancer 109: 866-871; Published online, 16 July 2013; doi:10.1038/bjc.2013.401
The association of waiting times from diagnosis to surgery with survival in women with localised breast cancer in England Open
M T Redaniel, R M Martin, S Cawthorn, J Wade and M Jeffreys
British Journal of Cancer 109: 42-49; Published online, 25 June 2013; doi:10.1038/bjc.2013.317
Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support? Open
B Séroussi, C Laouénan, J Gligorov, S Uzan, F Mentré and J Bouaud
British Journal of Cancer 109: 1147-1156; Published online, 13 August 2013; doi:10.1038/bjc.2013.453
A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK Open
S Holt, G Bertelli, I Humphreys, W Valentine, S Durrani, D Pudney, M Rolles, M Moe, S Khawaja, Y Sharaiha, E Brinkworth, S Whelan, S Jones, H Bennett and C J Phillips
British Journal of Cancer 108: 2250-2258; Published online, 21 May 2013; doi:10.1038/bjc.2013.207
partner of